For investors seeking leadership with a history of creating significant value, Dr. Torres’s track record is clear and compelling.

In 2001, he founded VBI Vaccines, a biotechnology company he built from the ground up. As its leader, he successfully advanced its scientific and corporate initiatives. His experience in transforming pioneering science into a successful public company provides CancerMune with an invaluable blueprint for growth, market leadership, and shareholder success.

Dr. Torres’s entrepreneurial success is built on a foundation of elite scientific achievement. His work in immunoinformatics and protein engineering has led to numerous accolades, including the prestigious Roche-Syntex Rosenkranz Award for his contributions to medicine. He is a Fellow of the American Association for the Advancement of Science (AAAS) and a Professor at the University of California, Davis, where he holds an appointment at the NCI-designated Comprehensive Cancer Center.

Dr. Torres’s relentless drive is rooted in his early life in the mountains of Puerto Rico, where he became the first in his family to achieve every level of education from high school to a university professorship. This formative experience forged in him a profound commitment to using science to solve humanity’s most critical challenges. Today, that same tenacity and vision are the driving forces behind CancerMune’s quest to develop lifesaving diagnostics and immunotherapies for patients worldwide.

Dr. Vazquez’s path was defined by overcoming immense challenges. Growing up in a medically underserved community in Puerto Rico, he developed a deep-seated drive to serve. This calling led him to eight years of decorated service as a U.S. Marine, where he was recognized for outstanding leadership during a combat tour in Iraq. This experience instilled in him an unparalleled level of discipline and the ability to execute complex missions under extreme pressure—qualities he now brings to leading CancerMune.

Driven by a desire to heal, Dr. Vazquez pursued an elite academic path to tackle medicine’s toughest problems. He earned a Ph.D. in Neuroscience from UC Berkeley, supported by the prestigious National Science Foundation Graduate Research Fellowship. His intellectual curiosity led to collaborations at Stanford and UCSF, pushing the boundaries of translational medicine.

He then earned his M.D. from the UC Davis School of Medicine, where he completed neurosurgery sub-internships with Honors at UC Davis, Stanford, and Yale. Poised for a competitive career as a neurosurgeon, he was at the pinnacle of clinical training.

It was at this critical juncture that Dr. Vazquez made a strategic choice. He recognized that while a career in neurosurgery would allow him to save one life at a time, the platform he co-founded at CancerMune offered a different, more profound opportunity: to impact millions.

He set aside his neurosurgical ambitions to dedicate himself fully to his role as CEO. This decision underscores his ultimate commitment—not to a single career path, but to a singular mission: leveraging breakthrough science and AI-driven technology to create scalable solutions that will redefine the future of cancer treatment for patients everywhere.

Dr. Tenborg has a proven history of managing complex biological challenges on a global scale. At the United Nations (UN), she collaborated with world leaders to architect the UN Global Rinderpest Action Plan, a strategic initiative to prevent the re-emergence of a devastating disease. She honed her skills in data analytics and predictive modeling at Metabiota, developing systems to improve global resilience to epidemics.

This high-level strategic experience is complemented by decisive, on-the-ground leadership. As part of the USDA Taskforce, she was deployed to help contain a virulent disease outbreak in California. This ability to operate at both the 30,000-foot view and the front lines makes her uniquely qualified to navigate the complexities of our preclinical drug development pipeline.

Dr. Tenborg’s journey is rooted in a deep understanding of the powerful link between animal and human health—a concept central to our strategy at CancerMune. Her background as a Doctor of Veterinary Medicine from UC Davis and a research fellow at the Stanford University School of Medicine, where she studied immunology, gives us a critical edge. By leading our canine cancer trials, she generates crucial data that directly informs and de-risks our human clinical programs.

Crucially, Dr. Tenborg thinks like a founder because she is one. She co-founded ToGo Vet, a veterinary tech startup that leverages AI to improve healthcare access. This entrepreneurial mindset ensures that our preclinical programs are not only scientifically rigorous but also efficient, strategic, and laser-focused on our commercial goals.

Dr. Li’s work is not just part of our story—it’s where our story began. During her postdoctoral fellowship at the University of California, Davis, she worked directly with CancerMune co-founder Dr. Jose V. Torres to design and validate novel vaccine strategies. It was this highly productive research that led to the development of the candidate cancer vaccines that are now core assets of CancerMune’s intellectual property. Her deep expertise in immunology and cancer vaccine design provides a powerful and direct link between our foundational science and our future commercial success.

Dr. Li’s expertise is built upon a foundation of elite medical and scientific training. She earned her M.D. and completed a dermatology residency before pursuing advanced graduate studies at the prestigious Shanghai Medical College of Fudan University, one of China’s top-ranked medical schools. There, she earned both a Master's and a Ph.D. in Pathogen Biology, receiving an award for her "Excellent Graduation Dissertation."

This dual background as both a clinician and a research scientist gives her a unique perspective. She has firsthand experience with the limitations of existing treatments, which fuels her passion for developing truly transformative therapies. Her work is driven by a profound and unwavering commitment to relieving patient suffering and creating cures.

Dr. Sepúlveda honed his expertise at Hewlett-Packard (HP), where he pioneered and deployed proprietary machine-learning algorithms that had a significant impact on the company's global sales and marketing strategies. He created AI-driven tools that analyzed massive data sets, influencing company-wide policy and driving operational effectiveness.

Leveraging this high-impact corporate experience, he founded his own successful AI firm, Pronto Analytics. For over 15 years, he has led his team in developing sophisticated, multi-platform data analysis applications, solidifying his reputation as a leader who can build and commercialize cutting-edge AI technology from the ground up.

At CancerMune, Dr. Sepúlveda is deploying his mastery of AI and data modeling to tackle his most important challenge yet: decoding the intricate language of the immune system. His team is developing novel immunoinformatics algorithms to predict cancer antigens with unparalleled speed and accuracy, dramatically accelerating the design of our diagnostics and immunotherapies.

His leadership in the field was recognized with the prestigious Wolfram Innovator Award, a testament to his ongoing contributions to the cutting edge of computer science. This award-winning expertise is now the driving force behind our technological platform and a core component of our competitive advantage.